Page 357 - Haematologica Vol. 109 - July 2024

CASE REPORT
Contributions
NS, DC, MG were responsible for patient care and finalized the manuscript. DK was responsible for the radiology images. MF and SB wrote the manuscript. MJ, MG and AM supervised the study.
References
1. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review (CSR) 1975-2018. Cronin KA eds. 2020.
2. Kegyes D, Constantinescu C, Vrancken L. Patient selection for CAR T or BiTE therapy in multiple myeloma: which treatment for each patient? J Hematol Oncol. 2022;15(1):78.
3. Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-cell– redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232-2244.
4. Chanan-Khan A, Miller KC, Takeshita K, et al. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia CLL. Blood. 2005;106(10):3348-3352.
5. Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-7420.
6. Budde LE, Assouline S, Sehn LH, et al. Single-agent
Data-sharing statement
Not applicable as no datasets were generated and/or analyzed for this study.
mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study. J Clin Oncol. 2022;10;40(5):481-491.
7. Aue G, Njuguna N, Tian X, et al. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica. 2009;94(9)1266-1273.
8. Leipold AM, Werner RA, Düll J, et al. Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma. Leukemia. 2023;37(3):650-658.
9. Jamet B, Bodet-Milin C, Moreau P, Kraeber-Bodéré F, Touzeau C. 2-[18F]FDG PET/CT flare-up phenomena following T-cell engager bispecific antibody in multiple myeloma. Clin Nucl Med. 2023;48(5):e230-e231.
Haematologica | 109 July 2024
2371